Network pharmacology and molecular docking reveal the mechanism of resveratrol in oral squamous cell carcinoma treatment
10.12016/j.issn.2096-1456.2024.03.003
- Author:
CHEN Hongjun
1
;
LEI Qi
2
;
WANG Zhilin
2
;
ZHONG Xiaowu
3
;
QIU Ya
4
;
LI Lihua
1
Author Information
1. Department of Stomatology, Affiliated Hospital of North Sichuan Medical College
2. Department of Stomatology, North Sichuan Medical College
3. Clinical Laboratory Department of Affiliated Hospital of Chuanbei Medical College
4. Medical Research Center of Affiliated Hospital of North Sichuan Medical College
- Publication Type:Journal Article
- Keywords:
resveratrol / oral squamous cell carcinoma / network pharmacology / molecular docking / Src tyro-sine kinase / epidermal growth factor receptor / estrogen receptor gene 1 / phosphatidylinositol 3 kinase/protein kinase B signaling pathway
- From:
Journal of Prevention and Treatment for Stomatological Diseases
2024;32(3):178-187
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the molecular mechanism of resveratrol (RES) in the treatment of oral squamous cell carcinoma (OSCC) through the use of biological information methods such as network pharmacology and molecular docking and to provide a theoretical reference for the clinical application of RES in the treatment of OSCC.
Methods:The Swiss Target Prediction(http://www.swisstargetprediction.ch), SEA (http://sea.bkslab.org)database, and Pharm mapper database(http://lilab-ecust.cn) were used to retrieve RES-related targets, and the DISGENET (www.disgenet.org), OMIM (https://omim.org) and GeneCards (https://www.genecards.org) databases were used to screen OSCC disease targets. The intersection of drugs and disease targets was determined, and Cytoscape 3.7.2 software was used to construct a "drug-diseasetarget pathway" network. The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database was used to construct a target protein interaction network, and the DAVID database was used for enrichment analysis of key proteins. Finally, molecular docking validation of key proteins was performed using AutoDock and PyMOL. The enrichment analysis and molecular docking results were integrated to predict the possible molecular mechanisms of RES treatment in OSCC; western blot was used to determine the effect of resveratrol at different concentrations (50, 100) μmol/L on the expression of Src tyrosine kinase (SRC), epidermal growth factor receptor (EGFR), estrogen receptor gene 1 (ESR1), and phosphatidylinositol 3 kinase/protein kinase B (PI3K/AKT) signaling pathway proteins in OSCC HSC-3 cells.
Results:A total of 243 targets of RES drugs and 6 094 targets of OSCC were identified. A total of 116 potential common targets were obtained by intersecting drugs with disease targets. These potential targets mainly participate in biological processes such as in vivo protein self-phosphorylation, peptide tyrosine phosphorylation, transmembrane receptor protein tyrosine kinase signaling pathway, and positive regulation of RNA polymerase Ⅱ promoter transcription, and they interfere with the PI3K/AKT signaling pathway to exert anti-OSCC effects. The docking results of resveratrol with OSCC molecules indicated that key targets, such as EGFR, ESR1, and SRC, have good binding activity. The results of cell-based experiments showed that resveratrol inhibited the protein expression of SRC, EGFR, ESR1, p-PI3K, and p-AKT in HSC-3 cells in a dose-dependent manner.
Conclusion:RES can inhibit the expression of its targets EGFR, ESR1, SRC, p-PI3K, and p-AKT in OSCC cells.
